Why Pfizer’s Deal May Change the System of Taxing Multinationals by VICTOR FLEISCHER

By VICTOR FLEISCHER

The United States approach has been a failure, and a $152 billion drug merger could nudge tax-writing committees in Washington into action.

Published: November 25, 2015 at 12:00AM

from NYT Business Day http://ift.tt/1QG2BLv

from WordPress http://ift.tt/1ShMpOd
via Hadi Aboukhater